Search research articles
Contact Us
Filters
Showing results (1-10 of 40) with videos related to
Page
of 4
Sort By:
World Journal of Clinical Cases
|
August 6, 2015
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Alberto Gajofatto, Maria Donata Benedetti
Expert Review of Neurotherapeutics
|
November 14, 2014
Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy
Massimiliano Calabrese, Alberto Gajofatto, Maria Donata Benedetti
Expert Review of Neurotherapeutics
|
November 5, 2016
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives
Alberto Gajofatto, Marco Turatti, Maria Donata Benedetti
Drug, Healthcare and Patient Safety
|
December 31, 2015
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
Alberto Gajofatto, Marco Turatti, Salvatore Monaco, et al.
Disease Markers
|
December 11, 2013
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis
Alberto Gajofatto, Massimiliano Calabrese, Maria Donata Benedetti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
May 14, 2011
Multiple radiculopathy as the presenting manifestation of primary spinal leptomeningeal B cell lymphoma detected by flow cytometry of cerebrospinal fluid
Manuel Cappellari, Fabio Benedetti, Antonio Fiaschi, et al.
Mini Reviews in Medicinal Chemistry
|
August 12, 2008
Azathioprine in multiple sclerosis
Paolo Invernizzi, Maria Donata Benedetti, Sarah Poli, et al.
European Neurology
|
September 18, 2014
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study
Alberto Gajofatto, Maria Rachele Bianchi, Luciano Deotto, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
May 13, 2010
Long survival and clinical stability in Marburg's variant multiple sclerosis
Marco Turatti, Alberto Gajofatto, Francesca Rossi, et al.
International Journal of Molecular Sciences
|
December 17, 2011
Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?
Alberto Gajofatto, Matilde Bongianni, Gianluigi Zanusso, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 40) with videos related to
Sort By:
Page
of 4
World Journal of Clinical Cases
|
August 6, 2015
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Alberto Gajofatto, Maria Donata Benedetti
Expert Review of Neurotherapeutics
|
November 14, 2014
Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy
Massimiliano Calabrese, Alberto Gajofatto, Maria Donata Benedetti
Expert Review of Neurotherapeutics
|
November 5, 2016
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives
Alberto Gajofatto, Marco Turatti, Maria Donata Benedetti
Drug, Healthcare and Patient Safety
|
December 31, 2015
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
Alberto Gajofatto, Marco Turatti, Salvatore Monaco, et al.
Disease Markers
|
December 11, 2013
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis
Alberto Gajofatto, Massimiliano Calabrese, Maria Donata Benedetti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
May 14, 2011
Multiple radiculopathy as the presenting manifestation of primary spinal leptomeningeal B cell lymphoma detected by flow cytometry of cerebrospinal fluid
Manuel Cappellari, Fabio Benedetti, Antonio Fiaschi, et al.
Mini Reviews in Medicinal Chemistry
|
August 12, 2008
Azathioprine in multiple sclerosis
Paolo Invernizzi, Maria Donata Benedetti, Sarah Poli, et al.
European Neurology
|
September 18, 2014
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study
Alberto Gajofatto, Maria Rachele Bianchi, Luciano Deotto, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
May 13, 2010
Long survival and clinical stability in Marburg's variant multiple sclerosis
Marco Turatti, Alberto Gajofatto, Francesca Rossi, et al.
International Journal of Molecular Sciences
|
December 17, 2011
Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?
Alberto Gajofatto, Matilde Bongianni, Gianluigi Zanusso, et al.
Page
of 4